BerGenBio ASA
Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. The company is based in Oslo, Norway.
BerGenBio ASA (BRRGF) - Total Liabilities
Latest total liabilities as of June 2025: $19.75 Million USD
Based on the latest financial reports, BerGenBio ASA (BRRGF) has total liabilities worth $19.75 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
BerGenBio ASA - Total Liabilities Trend (2014–2024)
This chart illustrates how BerGenBio ASA's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
BerGenBio ASA Competitors by Total Liabilities
The table below lists competitors of BerGenBio ASA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Aic Mines Ltd
AU:A1M
|
Australia | AU$97.62 Million |
|
Imperial Metals Corporation
PINK:IPMLF
|
USA | $808.45 Million |
|
Harbin Sayyas Windows Co. Ltd. A
SHE:301227
|
China | CN¥575.69 Million |
|
Yanpai Filtration Technology Co.Ltd.
SHE:301081
|
China | CN¥1.14 Billion |
|
St.Shine Optical Co Ltd
TWO:1565
|
Taiwan | NT$1.71 Billion |
|
Cardinal Ethanol LLC
OTCGREY:CRDE
|
USA | $96.54 Million |
|
APAC Opto Electronics
TWO:4908
|
Taiwan | NT$169.25 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down BerGenBio ASA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BerGenBio ASA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BerGenBio ASA (2014–2024)
The table below shows the annual total liabilities of BerGenBio ASA from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $33.09 Million | -29.37% |
| 2023-12-31 | $46.86 Million | -40.08% |
| 2022-12-31 | $78.21 Million | +18.84% |
| 2021-12-31 | $65.81 Million | -3.18% |
| 2020-12-31 | $67.97 Million | +34.27% |
| 2019-12-31 | $50.62 Million | +21.85% |
| 2018-12-31 | $41.55 Million | +22.24% |
| 2017-12-31 | $33.99 Million | +59.81% |
| 2016-12-31 | $21.27 Million | +20.52% |
| 2015-12-31 | $17.64 Million | -421.46% |
| 2014-12-31 | $-5.49 Million | -- |